[Does insulin glargin (lantus) lead to a progression in diabetic retinopathy?].
Meyer
C H
CH
Kroll
P
P
Hammes
H-P
HP
D017327:Clinical Trials, Phase IV as Topic; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy*; D003930:Diabetic Retinopathy / Q000139:chemically induced* / Q000175:diagnosis; D018450:Disease Progression; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D000069036:Insulin Glargine; D007336:Insulin, Isophane / Q000627:therapeutic use / Q000633:toxicity; D049528:Insulin, Long-Acting; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D012164:Retinal Diseases / Q000139:chemically induced / Q000175:diagnosis; D012171:Retinal Vessels / Q000187:drug effects / Q000473:pathology; D014481:United States; D014486:United States Food and Drug Administration; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D007328:Insulin; D049528:Insulin, Long-Acting; D042461:Vascular Endothelial Growth Factor A; D000069036:Insulin Glargine; D007336:Insulin, Isophane; D007334:Insulin-Like Growth Factor I